

## 論 文 要 旨

**Newly identified poor prognostic factors for adult T-cell  
leukemia-lymphoma treated with allogeneic hematopoietic stem  
cell transplantation**

氏名 徳 永 雅 仁

To explore pre-transplantation prognostic factors for adult T-cell leukemia-lymphoma (ATL), we retrospectively analyzed allogeneic hematopoietic stem cell transplantation (allo-HSCT) in 70 patients at our institute (63 acute type and 7 lymphoma type patients). Forty-five patients died after HSCT, and the 3-year overall survival (OS) rate was 35.2%. By univariate analysis, the adverse prognostic factors for OS were performance status  $\geq 2$ , hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score  $\geq 3$ , European Group for Blood and Marrow Transplantation (EBMT) risk score  $\geq 5$ , HSCT from an HLA-mismatched donor, serum soluble interleukin-2 receptor (sIL-2R) level  $\geq 10000$  U/mL, lymphocyte count  $\geq 4000/\mu\text{L}$ , and hemoglobin  $< 9$  g/dL at the time of HSCT. EBMT risk score and sIL-2R were identified as significant adverse prognostic factors using multivariate analysis. This analysis clearly demonstrates for the first time that HCT-CI and EBMT risk scores are reliable prognostic factors for ATL patients receiving allo-HSCT.